CryoPort (NASDAQ:CYRX) (NASDAQ: CYRX) is a global provider of cryogenic logistics solutions for the life sciences industry. The company specializes in the temperature-controlled transportation and storage of biologic materials, including cell and gene therapies, vaccines, blood products and other temperature-sensitive compounds. Cryoport’s offerings span from dry vapor shippers and temperature monitoring devices to comprehensive shipment management services designed to safeguard the integrity of critical research and therapeutic shipments.
Core to Cryoport’s business is its Cryoport Express® service, a turnkey solution that integrates specialized shipping containers, real-time temperature tracking, data analytics and regulatory expertise. This platform supports preclinical and clinical trial phases, enabling pharmaceutical and biotech clients to move samples and therapies across international borders with confidence. In addition, Cryoport provides storage services, on-site temperature management and tailored logistics consulting to optimize clients’ cold-chain workflows.
Originally founded in 2010 as BioStorage Technologies, the company rebranded to Cryoport in 2014 to reflect its broader cold chain logistics focus. Over the years, Cryoport has expanded its portfolio through strategic partnerships, technology innovations and targeted acquisitions, reinforcing its position in the growing cell and gene therapy market. The company’s solutions have been used in thousands of clinical trials and commercial launches worldwide.
Cryoport operates from headquarters in Irvine, California, with regional hubs in Europe, Asia and Latin America to support 24/7 logistics. Under the leadership of President and CEO Tim O’Malley, the executive team emphasizes continuous process improvement and regulatory compliance to meet evolving global standards. Cryoport’s global infrastructure and specialized workforce aim to deliver reliable, end-to-end cryogenic logistics for customers pushing the frontiers of medical science.
